SAT0196 Time to discontinuation of biologic therapy by mechanism of action in rheumatoid arthritis: results from the ontario best practice research initiative (OBRI) cohort
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2131
Abstract: Background: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However, time to discontinuation may be related to mechanism of action.… read more here.
Keywords: tnfi; research; response; time ... See more keywords
OP0225 SERIOUS INFECTIONS IN OFFSPRING EXPOSED IN UTERO TO NON-TNFI BIOLOGICS AND TOFACITINIB
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.5900
Abstract: Background During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc part have the potential to transfer across the placenta,… read more here.
Keywords: tnfi; non tnfi; tnfi biologics; biologics tofacitinib ... See more keywords